Boston Scientific Corp financial data

Symbol
BSX on NYSE
Industry
Surgical & Medical Instruments & Apparatus
Location
300 Boston Scientific Way, Marlborough, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Feb 18, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 144 % +6.32%
Quick Ratio 47.1 % -6.98%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.48B shares +0.59%
Entity Public Float 113B USD +43.2%
Common Stock, Value, Issued 17M USD 0%
Weighted Average Number of Shares Outstanding, Basic 1.47B shares +1.27%
Weighted Average Number of Shares Outstanding, Diluted 1.49B shares +1.53%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 16.7B USD +17.6%
Operating Income (Loss) 2.6B USD +11.1%
Nonoperating Income (Expense) -311M USD -9.12%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 2.28B USD +15%
Income Tax Expense (Benefit) 436M USD +10.9%
Earnings Per Share, Basic 1.26 USD/shares +16.7%
Earnings Per Share, Diluted 1.25 USD/shares +16.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 414M USD -52.1%
Inventory, Net 2.81B USD +13.1%
Other Assets, Current 831M USD +33.8%
Assets, Current 6.92B USD +6.23%
Deferred Income Tax Assets, Net 3.66B USD -4.84%
Property, Plant and Equipment, Net 3.29B USD +15.2%
Operating Lease, Right-of-Use Asset 449M USD +2.28%
Intangible Assets, Net (Excluding Goodwill) 6.68B USD +11.3%
Goodwill 17.1B USD +18.8%
Other Assets, Noncurrent 1.75B USD +14.6%
Assets 39.4B USD +12.1%
Accounts Payable, Current 960M USD +1.91%
Employee-related Liabilities, Current 1.29B USD +22.6%
Accrued Liabilities, Current 2.77B USD +4.8%
Liabilities, Current 6.4B USD +29.7%
Long-term Debt and Lease Obligation 8.97B USD +4.63%
Accrued Income Taxes, Noncurrent 357M USD -24%
Deferred Income Tax Liabilities, Net 155M USD +15.7%
Operating Lease, Liability, Noncurrent 401M USD +2.82%
Other Liabilities, Noncurrent 1.87B USD -4.93%
Accumulated Other Comprehensive Income (Loss), Net of Tax 275M USD +461%
Retained Earnings (Accumulated Deficit) 2.67B USD +226%
Stockholders' Equity Attributable to Parent 21.8B USD +12.9%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 22B USD +12.7%
Liabilities and Equity 39.4B USD +12.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 164M USD -13.7%
Net Cash Provided by (Used in) Financing Activities 1.57B USD
Net Cash Provided by (Used in) Investing Activities -285M USD +41.1%
Common Stock, Shares Authorized 2B shares 0%
Common Stock, Shares, Issued 1.74B shares +0.51%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 1.44B USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 606M USD -42.6%
Deferred Tax Assets, Valuation Allowance 1.27B USD +3.93%
Deferred Tax Assets, Gross 4.99B USD -0.78%
Operating Lease, Liability 482M USD +3.43%
Depreciation 412M USD +12.3%
Payments to Acquire Property, Plant, and Equipment 179M USD +61.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 2.08B USD +51.4%
Lessee, Operating Lease, Liability, to be Paid 564M USD +4.64%
Property, Plant and Equipment, Gross 6.83B USD +7.63%
Operating Lease, Liability, Current 81M USD +6.58%
Operating Lease, Weighted Average Discount Rate, Percent 0.04 pure -22.2%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 82M USD +10.8%
Deferred Tax Assets, Operating Loss Carryforwards 774M USD +4.03%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 50M shares 0%
Unrecognized Tax Benefits 506M USD +8.35%
Amortization of Intangible Assets 856M USD +3.38%
Depreciation, Depletion and Amortization 304M USD +6.67%
Deferred Tax Assets, Net of Valuation Allowance 3.72B USD -2.28%
Interest Expense 305M USD +15.1%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%